Janux Therapeutics/$JANX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Janux Therapeutics

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Ticker

$JANX
Primary listing

Industry

Biotechnology

Employees

91

ISIN

US47103J1051

JANX Metrics

BasicAdvanced
$1.5B
-
-$1.37
3.24
-

What the Analysts think about JANX

Analyst ratings (Buy, Hold, Sell) for Janux Therapeutics stock.

Bulls say / Bears say

Janux Therapeutics successfully closed a public offering, raising $402.5 million to advance its clinical pipeline, indicating strong financial backing for future developments. (Janux Therapeutics)
The company reported a $7.5 million milestone payment from Merck, reflecting progress in its collaborative efforts and validation of its TRACTr and TRACIr platforms. (Business Wire)
Analysts have raised the price target for Janux Therapeutics to $100.00, suggesting confidence in the company's growth potential and future performance. (American Banking and Market News)
Significant stock sales by major shareholders, totaling approximately $23.8 million, may indicate reduced confidence or profit-taking, potentially impacting investor sentiment. (Investing.com)
Despite promising early-stage results, analysts believe Janux has not yet established a strong competitive edge, which could affect its attractiveness for partnerships or acquisitions. (Nasdaq)
The company's reliance on ongoing clinical trials for its lead candidates, JANX007 and JANX008, means that any setbacks or delays could negatively impact its stock performance and investor confidence. (Business Wire)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.

JANX Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

JANX Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $JANX

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs